Brokerages predict that Xencor Inc (NASDAQ:XNCR) will announce earnings per share of ($0.27) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Xencor’s earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.06). Xencor posted earnings of ($0.21) per share in the same quarter last year, which indicates a negative year over year growth rate of 28.6%. The firm is expected to issue its next earnings report on Tuesday, February 27th.
On average, analysts expect that Xencor will report full-year earnings of ($1.10) per share for the current year, with EPS estimates ranging from ($1.29) to ($0.85). For the next year, analysts forecast that the company will post earnings of ($1.67) per share, with EPS estimates ranging from ($2.12) to ($1.15). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Xencor.
Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative net margin of 148.29% and a negative return on equity of 15.26%.
In related news, major shareholder John S. Stafford III acquired 5,349 shares of the stock in a transaction dated Friday, November 24th. The shares were acquired at an average price of $19.85 per share, for a total transaction of $106,177.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder John S. Stafford III acquired 9,215 shares of the stock in a transaction dated Thursday, December 14th. The stock was bought at an average price of $20.76 per share, for a total transaction of $191,303.40. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 36,477 shares of company stock worth $738,031. 4.14% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Great West Life Assurance Co. Can boosted its stake in Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,005 shares in the last quarter. Legal & General Group Plc boosted its stake in Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Xencor during the third quarter worth $201,000. Citadel Advisors LLC acquired a new stake in Xencor during the second quarter worth $224,000. Finally, Teacher Retirement System of Texas acquired a new stake in Xencor during the fourth quarter worth $291,000. Institutional investors and hedge funds own 77.50% of the company’s stock.
Xencor (NASDAQ XNCR) opened at $22.18 on Wednesday. Xencor has a 52-week low of $18.55 and a 52-week high of $28.64. The company has a market cap of $1,011.54, a P/E ratio of -22.18 and a beta of 1.97.
WARNING: “-$0.27 EPS Expected for Xencor Inc (XNCR) This Quarter” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/07/0-27-eps-expected-for-xencor-inc-xncr-this-quarter.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.